- Home
- NODK vs ZNTL Comparison
NODK vs ZNTL Comparison
Compare NODK & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NODK | ZNTL |
|---|---|---|
| Founded | 1946 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 265.8M | 156.7M |
| IPO Year | 2016 | 2020 |
Fundamental Metrics
Financial Performance| Metric | NODK | ZNTL |
|---|---|---|
| Price | $13.03 | $2.34 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $5.80 |
| AVG Volume (30 Days) | 19.5K | ★ 580.7K |
| Earning Date | 03-06-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.03 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $285,050,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $12.01 | $1.01 |
| 52 Week High | $14.70 | $3.95 |
Technical Indicators
Market Signals| Indicator | NODK | ZNTL |
|---|---|---|
| Relative Strength Index (RSI) | 43.90 | 45.82 |
| Support Level | $12.34 | $1.28 |
| Resistance Level | $13.70 | $2.69 |
| Average True Range (ATR) | 0.41 | 0.19 |
| MACD | -0.02 | -0.05 |
| Stochastic Oscillator | 29.06 | 31.55 |
Price Performance
Historical ComparisonAbout NODK NI Holdings Inc.
NI Holdings Inc is a stockholding company. Through its subsidiaries, the company operates in the insurance industry, offering homeowners and farmowners insurance policies, crop insurance policies, home insurance policies, etc. These insurance products are distributed through a network of exclusive and independent agents across the United States. The group's reportable segments are: Private Passenger Auto, Non-Standard Auto, Home and Farm, Crop, and All Other (which mainly consists of commercial, assumed reinsurance, and its excess liability business). Maximum revenue is generated from the Home and Farm segment.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.